acut
lower
respiratori
tract
infect
persist
public
health
problem
despit
remark
advanc
antibiot
therapi
diagnost
tool
prevent
campaign
intens
care
respiratori
infect
still
among
primari
caus
death
worldwid
signific
chang
mortal
last
decad
childhood
acut
communityacquir
pneumonia
one
lead
caus
morbid
mortal
develop
countri
children
receiv
prior
antibiot
therapi
main
bacteri
caus
clinic
pneumonia
develop
countri
streptococcu
pneumonia
haemophilu
influenza
type
b
main
viral
caus
respiratori
syncyti
viru
respiratori
syncyti
viru
rsv
pneumoviru
famili
paramyxovirida
infect
nearli
children
within
first
year
life
primari
rsv
infect
caus
sever
bronchiol
pneumonia
associ
significantli
increas
risk
develop
wheez
childhood
last
teenag
year
symptomat
reinfect
occur
everi
age
group
frequenc
sever
symptom
highest
children
year
age
describ
sever
respiratori
virus
pandem
influenza
viru
strain
human
coronaviru
caus
sar
believ
immun
respons
play
critic
role
outcom
rsvinduc
bronchiol
pneumonia
acut
rsv
infect
abl
induc
exacerb
diseas
due
immunemedi
pulmonari
injuri
result
sever
morbid
mortal
therefor
identifi
novel
approach
modul
virusinduc
immunopatholog
would
benefici
treat
acut
rsv
infect
sever
studi
demonstr
certain
lactic
acid
bacteria
lab
strain
exert
benefici
effect
host
immunomudulatori
activ
regard
studi
center
whether
immunoregulatori
probiot
lab
immunobiot
might
suffici
stimul
common
mucos
immun
system
provid
protect
mucos
site
distant
gut
studi
laboratori
demonstr
oral
administ
lab
abl
increas
pneumonia
clearanc
rate
lung
blood
improv
surviv
infect
mice
reduc
lung
injuri
moreov
found
effect
lab
treatment
relat
upregul
respiratori
innat
adapt
immun
respons
addit
consid
nasal
rout
induc
system
respiratori
immun
respons
superior
obtain
use
oral
stimul
also
focus
abil
nasal
stimul
immunobiot
improv
respiratori
immun
respons
studi
show
nasal
administ
lab
capabl
modul
lung
immun
increas
resist
pneumonia
immunocompet
immunocompromis
mice
mani
case
nasal
prime
effect
oral
administr
benefici
modul
respiratori
immun
recent
laboratori
studi
capac
immunobiot
improv
respiratori
antivir
immun
respons
mimic
proinflammatori
physiopatholog
consequ
rna
viral
infect
lung
induc
rsv
infect
use
experiment
model
lung
inflamm
base
administr
artifici
tolllik
receptor
retino
gene
rigi
ligand
dsrna
analog
poli
c
vivo
studi
use
mice
demonstr
nasal
administ
poli
c
result
neutrophil
pulmonari
inflamm
bronchiolar
epitheli
hypertrophi
interstiti
edema
alter
lung
function
chang
accompani
elev
level
interleukin
il
rant
monocyt
chemotact
protein
mip
type
interferon
ifn
bronchoalveolar
lavag
bal
evalu
effect
two
lactobacillu
strain
lactobacillu
rhamnosu
l
rhamnosu
mice
model
found
oral
administ
benefici
regul
balanc
proinflammatori
mediat
lung
poli
c
challeng
mice
allow
effect
control
inflammatori
respons
avoid
tissu
damag
moreov
studi
demonstr
abl
increas
number
cell
gut
induc
mobil
cell
respiratori
mucosa
improv
local
product
activ
lung
antigen
present
cell
apc
result
suggest
potent
induc
antivir
cytokin
may
use
prophylact
agent
control
respiratori
viru
infect
howev
whether
nasal
prime
effect
oral
administr
benefici
modul
respiratori
immun
respons
trigger
poli
c
challeng
evalu
moreov
studi
use
real
challeng
respiratori
virus
rsv
need
order
conclus
demonstr
protect
effect
consid
background
aim
studi
investig
whether
nasal
administr
abl
improv
respiratori
antivir
defens
benefici
modul
immun
respons
trigger
activ
b
evalu
whether
viabil
indispens
modul
respiratori
immun
consid
report
heatkil
lactobacilli
strain
abl
improv
lung
defens
c
conclus
demonstr
protect
effect
evalu
capac
improv
resist
infant
mice
rsv
challeng
lactobacillu
rhamnosu
obtain
cerela
cultur
collect
chacabuco
san
miguel
de
argentina
strain
select
previous
report
immunomodulatori
capac
cultur
kept
freezedri
rehydr
use
follow
medium
pepton
g
trypton
g
meat
extract
g
distil
water
l
ph
cultur
h
final
log
phase
manrogosasharp
broth
mr
oxoid
bacteria
harvest
centrifug
g
min
wash
three
time
steril
moll
phosphat
buffer
salin
pb
ph
resuspend
steril
nonfat
milk
nonviabl
design
respect
obtain
follow
bacteria
kill
tyndal
water
bath
min
lack
bacteri
growth
confirm
use
mr
agar
plate
femal
balbc
mice
obtain
close
coloni
kept
tohoku
univers
hous
plastic
cage
room
temperatur
mice
hous
individu
experi
assay
paramet
studi
perform
mice
per
group
time
point
nasal
administ
differ
group
mice
consecut
day
dose
cellsmouseday
pb
treat
group
untreat
control
group
fed
convent
balanc
diet
ad
libitum
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
guidelin
anim
experiment
tohoku
univers
sendai
japan
present
studi
approv
institut
anim
care
use
committe
tohoku
univers
effort
made
minim
suffer
administr
viral
pathogen
molecular
pattern
poli
c
perform
day
two
day
treatment
lactobacilli
describ
previous
mice
lightli
anesthet
pb
contain
poli
c
equival
mgkg
bodi
weight
administ
dropwis
via
nare
control
anim
receiv
pb
mice
receiv
three
dose
poli
c
pb
hs
rest
period
administr
blood
sampl
obtain
cardiac
punctur
end
treatment
collect
heparin
tube
bal
sampl
obtain
describ
previous
briefli
trachea
expos
intub
cathet
sequenti
bronchoalveolar
lavag
perform
mous
inject
steril
pb
recov
fluid
centrifug
min
g
pellet
use
make
smear
stain
cell
count
fluid
frozen
subsequ
cytokin
analys
tumour
necrosi
factor
tnf
concentr
serum
bal
measur
commerci
avail
enzymelink
immunosorb
assay
elisa
techniqu
kit
follow
manufactur
recommend
r
system
mn
usa
protein
albumin
content
measur
quantit
increas
permeabl
barrier
lactat
dehydrogenas
ldh
activ
indic
gener
cytotox
determin
acellular
bal
fluid
protein
content
measur
bicinchonin
acid
assay
bca
protein
assay
pierc
biotechnolog
inc
rockford
il
albumin
content
determin
colorimetr
base
albumin
bind
bromcresol
green
use
albumin
diagnost
kit
wiener
lab
bueno
air
argentina
ldh
activ
express
unit
per
liter
bal
fluid
determin
measur
format
reduc
form
nicotinamid
adenin
dinucleotid
nad
use
wiener
reagent
procedur
wiener
lab
lung
wet
dri
weight
ratio
measur
previous
describ
wet
dri
weight
ratio
calcul
index
intrapulmonari
fluid
accumul
without
correct
blood
content
singl
lung
cell
mice
prepar
use
previous
describ
method
mice
anaesthet
diethyl
ether
kill
next
day
exsanguin
lung
remov
fine
minc
incub
min
u
collagenas
yakult
honsha
co
tokyo
japan
ml
rpmi
medium
sigma
tokyo
japan
dissoci
tissu
singl
cell
collagenasetr
minc
lung
gentli
tap
plastic
dish
remov
debri
erythrocyt
deplet
hypoton
lysi
cell
wash
rpmi
medium
supplement
uml
penicillin
mgml
streptomycin
resuspend
medium
supplement
heatinactiv
foetal
calf
serum
fc
cell
count
use
trypan
blue
exclus
resuspend
appropri
concentr
cellsml
lung
cell
suspens
preincub
antimous
monoclon
antibodi
fc
block
min
cell
incub
antibodi
mix
min
wash
fac
buffer
follow
antibodi
bd
pharmingen
use
antimous
antimous
antimous
antimous
antimous
antimous
antimous
antimous
mhciip
antimous
antimous
follow
incub
biotinyl
primari
antibodi
label
reveal
use
streptavidinpercp
case
cell
acquir
bd
flow
cytomet
bd
bioscienc
data
analyz
flowjo
softwar
treestar
total
number
cell
popul
determin
multipli
percentag
subset
within
seri
marker
neg
posit
gate
total
cell
number
determin
tissu
human
rsv
strain
grown
vero
cell
describ
murawski
et
al
briefli
vero
cell
infect
rsv
multipl
infect
moi
ml
dulbecco
modifi
eagl
medium
dmem
cell
infect
h
infect
ml
dmem
fetal
bovin
serum
sigma
tokyo
japan
penicillinstreptomycin
penstrep
sigma
tokyo
japan
ciprofloxacin
bayer
ad
flask
flask
incub
extens
syncytium
format
observ
cell
scrape
flask
sonic
three
time
per
time
w
ice
cell
debri
remov
centrifug
g
min
viru
supernat
sucros
densiti
gradient
purifi
store
sucros
uninfect
flask
treat
ident
gener
vero
cell
lysat
control
vivo
infect
mice
lightli
anesthet
isofluran
intranas
challeng
pfu
rsv
strain
lung
tissu
remov
without
bal
harvest
store
sucros
plaqu
assay
lung
homogen
use
pellet
pestl
centrifug
g
min
clarifi
supernat
twentyfourwel
tissu
cultur
plate
seed
vero
cellswel
dmem
contain
fb
penstrep
ciprofloxacin
cell
incub
overnight
medium
remov
confluent
monolay
serial
dilut
lung
tissueclarifi
supernat
absorb
monolay
sampl
run
triplic
well
plate
incub
h
optimum
infect
incub
supernat
remov
ml
fresh
dmem
medium
contain
contain
fb
penstrep
ciprofloxacin
overlaid
monolay
extens
syncytia
develop
overlay
remov
monolay
fix
ml
icecold
aceton
methanol
primari
rsv
antif
clone
chemicon
antig
mous
monoclon
rsv
glycoprotein
abcam
antibodi
ad
well
h
follow
secondari
horseradish
peroxidas
antimous
immunoglobulin
antibodi
antimous
igg
hrplink
antibodi
cell
signal
tehcnolog
h
plate
wash
twice
pb
contain
tween
sigma
antibodi
incub
step
individu
plaqu
develop
use
dab
substrat
kit
abcam
follow
manufactur
specif
result
immunoplaqu
assay
express
pfug
lung
experi
perform
triplic
result
express
mean
standard
deviat
sd
verif
normal
distribut
data
anova
use
tukey
test
pairwis
comparison
mean
use
test
differ
group
differ
consid
signific
p
order
evalu
chang
induc
nasal
administ
lab
respiratori
immun
system
determin
level
differ
cytokin
bal
figur
four
nasal
treatment
use
studi
increas
level
bal
howev
concentr
cytokin
significantli
higher
mice
mice
receiv
figur
treatment
also
abl
increas
bal
viabl
heatkil
l
rhamnosu
effici
improv
level
cytokin
l
rhamnosu
figur
bal
concentr
increas
immunobiot
nasal
treatment
observ
viabl
cell
effici
upregul
heatkil
strain
differ
found
level
compar
viabl
heatkil
lactobacilli
figur
evalu
level
serum
found
lactobacilli
treatment
induc
similar
chang
observ
respiratori
tract
figur
effici
increas
l
rhamnosu
treatment
highest
level
serum
observ
group
figur
serum
concentr
also
enhanc
immunobiot
nasal
treatment
viabl
heatkil
lactobacilli
equal
effect
improv
cytokin
whit
except
induc
significantli
lower
level
compar
treatment
figur
also
evalu
chang
induc
nasal
administ
lactobacilli
lung
immun
cell
use
flow
cytometri
slightli
increas
lung
cell
observ
lactobacillitr
mice
howev
studi
cell
abl
produc
within
popul
mice
receiv
show
signific
differ
compar
control
mice
figur
nasal
administ
increas
number
cell
lung
effici
increas
cell
popul
figur
enhanc
number
cell
lung
figur
modif
observ
number
cell
lactobacillitr
mice
figur
two
popul
myeloid
dc
defin
lung
use
mhcii
antibodi
describ
previous
cell
therefor
next
aim
evalu
effect
nasal
administ
lactobacilli
popul
dc
lung
significantli
increas
number
lung
dc
addit
enhanc
number
lung
dc
quantit
chang
detect
dc
popul
lung
mice
figur
addit
express
mhcii
dc
popul
significantli
improv
treatment
howev
l
rhamnosu
effici
l
rhamnosu
upregul
express
mhcii
lung
dc
figur
next
aim
evalu
effect
nasal
administ
lactobacilli
immun
respons
trigger
nasal
administr
viral
pathogenassoci
molecular
pattern
poli
c
previou
work
demonstr
nasal
challeng
mice
poli
c
significantli
alter
lung
function
induc
lung
injuri
experiment
model
alter
wet
dri
weight
ratio
observ
poli
c
challeng
figur
moreov
significantli
increas
level
ldh
activ
well
protein
albumin
concentr
found
bal
sampl
challeng
mice
indic
poli
c
produc
local
cellular
damag
impair
alveolarcapillari
barrier
figur
observ
nasal
administ
lactobacilli
prior
poli
c
challeng
significantli
reduc
wet
dri
weight
ratio
bal
ldh
figur
addit
treatment
abl
significantli
reduc
bal
protein
albumin
concentr
howev
l
rhamnosu
effici
strain
reduc
impair
alveolarcapillari
barrier
figur
pulmonari
immun
respons
induc
nasal
challeng
poli
c
effect
nasal
administ
lactobacilli
respons
next
evalu
previous
studi
level
kinet
bal
poli
c
challeng
effect
oral
administ
immunobiot
respons
signific
chang
induc
oral
treatment
immunobiot
found
level
therefor
cytokin
studi
work
nasal
administr
poli
c
significantli
increas
respiratori
level
proinflammatori
mediat
figur
previous
report
lactobacilli
treatment
significantli
increas
level
bal
howev
effici
enhanc
concentr
cytokin
figur
addit
modifi
group
level
cytokin
lower
l
rhamnosu
mice
compar
control
figur
poli
c
challeng
also
induc
increas
respiratori
level
level
cytokin
significantli
higher
lactobacillitr
mice
effici
achiev
effect
figur
nasal
challeng
poli
c
also
increas
cytokin
level
serum
previous
report
moreov
effect
treatment
product
serum
similar
found
bal
data
shown
also
studi
chang
lung
immun
cell
induc
nasal
administ
lactobacilli
poli
c
challeng
mice
figur
poli
c
administr
increas
cell
describ
previous
addit
work
also
observ
increas
cell
challeng
poli
c
figur
result
show
nasal
administ
lactobacilli
abl
increas
cell
lung
howev
level
cell
popul
mice
significantli
higher
observ
group
figur
differ
observ
lactobacillitr
mice
control
evalu
cell
figur
poli
c
challeng
also
increas
number
pulmonari
dc
compar
basal
level
experiment
group
figur
nasal
administr
l
rhamnosu
l
rhamnosu
significantli
increas
number
dc
cell
lung
compar
control
mice
show
improv
level
pulmonari
dc
figur
next
address
question
whether
chang
observ
respiratori
immun
system
caus
intervent
immunobiot
affect
outcom
rsv
infect
mice
therefor
infant
mice
nasal
treat
challeng
pfu
rsv
viral
load
lung
infect
mice
follow
five
day
challeng
figur
rsv
detect
lung
experiment
group
five
day
postinfect
group
show
peak
viru
count
day
challeng
howev
lactobacillitr
mice
show
significantli
lower
lung
viral
load
compar
control
mice
treatment
equal
effect
reduc
rsv
replic
lung
case
l
rhamnonu
viabl
bacteria
effect
heatkil
cell
improv
protect
respiratori
viral
infect
figur
addit
observ
significantli
differ
bodi
weight
infect
mice
compar
lactobacillitr
mice
control
figur
significantli
improv
bodi
weight
rsv
infect
mice
show
differ
compar
control
figur
also
evalu
marker
lung
tissu
damag
rsvinfect
mice
show
figur
challeng
rsv
significantli
increas
lung
wet
dri
weight
bal
protein
concentr
ldh
activ
marker
lung
tissu
damag
significantli
higher
rsvchalleng
control
mice
previous
treat
figur
contrari
lung
wet
dri
weight
bal
protein
concentr
bal
ldh
activ
mice
differ
control
figur
final
address
whether
improv
resist
rsv
induc
lactobacilli
treatment
relat
differenti
modul
cytokin
product
infect
figur
therefor
evalu
level
bal
serum
day
postinfect
concentr
day
challeng
observ
challeng
rsv
significantli
increas
level
cytokin
studi
experiment
group
also
detect
lactobacillitr
mice
show
significantli
higher
level
bal
control
treatment
effici
improv
product
factor
figur
addit
level
significantli
improv
treatment
nasal
administr
increas
product
respiratori
tract
moreov
effect
increas
bal
concentr
respons
rsv
challeng
figur
effect
treatment
product
serum
similar
found
bal
data
shown
present
work
studi
effect
nasal
administ
immunobiot
lactobacilli
respiratori
antivir
immun
respons
evalu
capac
improv
protect
infant
mice
rsv
infect
three
import
conclus
infer
result
present
studi
nasal
administ
differenti
modul
antivir
respiratori
immun
respons
b
nasal
prime
strain
increas
resist
infant
mice
rsv
infect
c
viabil
immunobiot
strain
necessari
condit
achiev
immunoregulatori
protect
effect
nasal
administ
differenti
modul
antivir
respiratori
immun
respons
previous
demonstr
nasal
administr
three
oncedaili
dose
poli
c
result
mark
impair
lung
function
accompani
inflammatori
cell
recruit
airway
product
proinflammatori
mediat
accordingli
present
work
observ
increas
ldh
activ
albumin
concentr
bal
well
increas
level
type
ifn
respiratori
tract
poli
c
challeng
mice
also
show
immun
respons
modul
prevent
nasal
administr
demonstr
addit
strain
differ
immunoregulatori
effect
administr
signific
effect
product
respons
poli
c
challeng
nasal
prime
effect
improv
level
demonstr
poli
c
elicit
secret
type
ifn
cytokin
respiratori
epitheli
cell
therefor
like
sourc
cytokin
follow
poli
c
administr
may
airway
epithelium
administr
would
signific
effect
respiratori
epitheli
cell
take
consider
upregul
sever
gene
involv
viral
defens
also
gene
major
import
develop
strong
respons
specul
may
play
import
role
improv
innat
specif
immun
respons
respiratori
viru
stimul
antivir
defens
epitheli
cell
figur
addit
previous
demonstr
nasal
administr
poli
c
activ
respiratori
dc
dc
cell
increas
cell
lung
indic
gener
respons
result
present
show
nasal
administr
capac
improv
respons
sinc
higher
level
bal
lung
cell
found
mice
moreov
show
administr
significantli
activ
dc
affect
achiev
consid
recent
studi
suggest
lung
dc
potent
elicit
respons
dc
specul
effici
stimul
dc
improv
respons
respiratori
tract
figur
nasal
treatment
lactobacilli
significantli
reduc
lung
injuri
caus
poli
c
administr
previous
suggest
would
valuabl
attenu
inflammatori
damag
pathophysiolog
alter
lung
challeng
viral
pathogenassoci
molecular
pattern
poli
ic
demonstr
significantli
improv
product
respons
poli
ic
howev
effici
upregul
level
cytokin
respiratori
tract
moreov
lung
tissu
injuri
marker
use
studi
significantli
lower
mice
receiv
strain
therefor
confirm
direct
connect
improv
level
induc
immunobiot
protect
lung
injuri
respiratori
poli
c
challeng
moreov
work
demonstr
cell
would
sourc
produc
poli
c
challeng
immun
cell
popul
would
quantit
function
modul
sinc
increas
level
cell
found
lung
mice
compar
control
receiv
figur
recent
weiss
et
al
demonstr
cell
produc
major
vivo
acut
rsv
infect
cell
popul
involv
protect
effect
lung
tissu
damag
therefor
increas
number
cell
induc
nasal
treatment
lactobacilli
could
import
role
protect
rsv
infect
similar
chang
observ
intestin
immun
oral
administr
demonstr
work
nasal
prime
lactobacilli
abil
improv
antivir
immun
use
differ
mechan
figur
moreov
consid
activ
host
immun
respons
rsv
infect
depend
complex
signal
event
initi
part
prr
rigi
coordin
signal
event
promot
product
cytokin
chemokin
lung
crucial
viru
clearanc
specul
nasal
treatment
would
benefici
modul
immun
respons
rsv
improv
resist
mice
viral
respiratori
infect
b
nasal
prime
strain
increas
resist
infant
mice
rsv
challeng
last
year
line
evid
show
nasal
administr
immunobiot
abl
increas
resist
respiratori
viral
infect
report
intranas
prime
l
rhamnosu
gg
balbc
mice
significantli
reduc
frequenc
accumul
symptom
induc
higher
surviv
rate
control
mice
challeng
influenza
viru
author
demonstr
l
rhamnosu
gg
significantli
increas
lung
nk
cell
activ
express
enhanc
respiratori
cellmedi
immun
respons
addit
report
recent
nasal
prime
lactobacilli
highli
effect
suppress
virusinduc
inflamm
pneumonia
viru
mous
model
nasal
prime
lactobacilli
result
mark
suppress
ifninduc
neutrophilactiv
tnf
respons
pneumoviru
infect
significantli
increas
resist
lethal
diseas
work
extend
find
demonstr
nasal
administ
immunobiot
abl
increas
protect
rsv
infect
infant
mice
observ
challeng
three
week
old
balbc
mice
rsv
significantli
alter
lung
function
induc
tissu
injuri
trigger
inflammatori
respons
line
previou
work
report
rsv
intranas
infect
led
signific
clinic
characterist
femal
balbc
mice
author
describ
ruffl
fur
ataxia
occur
earli
hour
postrsv
infect
continu
day
natur
human
rsv
infect
children
experiment
rsv
inocul
mice
result
promin
local
secret
proinflammatori
cytokin
rant
well
type
ifn
shown
type
ifn
contribut
clearanc
viru
earli
stage
rsv
infect
howev
continu
product
proinflammatori
mediat
exacerb
ill
tissu
injuri
late
stage
rsv
infect
interestingli
found
defici
rsv
challeng
affect
viral
load
led
markedli
increas
diseas
sever
enhanc
weight
loss
delay
recoveri
greater
influx
inflammatori
cell
lung
airway
enhanc
releas
inflammatori
mediat
therefor
acut
rsv
infect
imper
host
inflammatori
respons
tightli
regul
enabl
viru
elimin
limit
detriment
effect
inflamm
lung
tissu
adequ
balanc
proinflammatori
antiinflammatori
factor
essenti
safe
effect
antivir
immun
respons
moreov
consid
report
chang
peak
viral
titer
viral
clearanc
observ
ko
mabtreat
mice
compar
control
prevent
therapeut
approach
aim
increas
product
may
offer
mean
decreas
rsvinduc
immunopatholog
without
affect
viral
clearanc
demonstr
work
nasal
administr
improv
product
proinflammatori
mediat
respons
rsv
challeng
also
product
would
allow
effect
immunolog
clearanc
viru
without
affect
lung
tissu
similarli
result
use
poli
c
challeng
observ
strain
highest
capac
improv
level
effect
enhanc
viru
clearanc
protect
lung
inflammatori
damag
result
also
support
idea
modul
respiratori
rsv
infect
effect
way
improv
outcom
viral
diseas
moreov
demonstr
nasal
administ
immunobiot
interest
altern
achiev
immunoprotect
effect
follow
rsv
infect
initi
influx
nk
cell
site
infect
produc
cytotox
virusinfect
cell
follow
recruit
helper
cytotox
lymphocyt
site
infect
enhanc
differenti
lymphocyt
influenc
differenti
lymphocyt
contribut
gener
amplif
humor
cellular
immun
respons
rsvspecif
cell
respons
play
major
role
viral
clearanc
clinic
outcom
infect
cell
implic
immunopathogenesi
gener
immun
respons
favor
rsv
infect
especi
younger
host
rsvinduc
pulmonari
inflamm
mice
previous
found
caus
shift
cell
inflamm
rsv
use
multipl
mechan
induc
cell
respons
host
includ
rsv
g
effect
increas
product
basophil
induct
altern
activ
macrophag
moreov
excess
mucu
product
airway
plug
wheez
longlast
effect
lung
function
common
manifest
rsv
diseas
similar
asthma
involv
therefor
strategi
aim
improv
rsv
infect
would
benefici
modul
outcom
infect
especi
younger
host
work
show
nasal
administ
immunobiot
abl
improv
respiratori
respons
sinc
significantli
higher
level
found
respiratori
tract
lactobacillitr
mice
modul
respiratori
immun
potenti
immunobiot
strain
might
contribut
improv
respons
therebi
favor
protect
immun
viral
infect
rsv
c
viabil
immunobiot
strain
necessari
condit
achiev
immunoregulatori
protect
effect
studi
demonstr
nasal
administr
heatkil
immunobiot
abl
improv
resist
respiratori
pathogen
regard
earlier
studi
hori
et
al
show
nasal
administr
heatkil
l
casei
shirota
stimul
cellular
immun
respiratori
tract
significantli
increas
resist
adult
balbc
mice
influenza
viru
infect
author
investig
product
variou
cytokin
mediastin
lymphoid
node
cell
mice
receiv
l
casei
shirota
intranas
found
shirota
strain
strongli
induc
product
cell
import
cytokin
cytotox
cell
nk
cell
stimul
enhanc
cytokin
addit
level
improv
mediastin
lymphoid
node
cell
cultur
mice
administ
l
casei
shirota
intranas
influenza
viru
challeng
later
report
intranas
administr
heatkil
l
pentosu
strongli
enhanc
immun
product
nk
activ
respiratori
immun
system
protect
influenza
viru
infect
addit
mention
demonstr
prime
respiratori
mucosa
lactobacilli
result
full
protect
otherwis
lethal
sever
pneumoviru
infect
protect
observ
respons
live
heatkil
l
plantarum
l
reuteri
work
demonstr
nasal
treatment
heatkil
immunobiot
result
diminish
viru
recoveri
multipl
time
point
promin
suppress
product
virusinduc
proinflammatori
mediat
result
work
line
previou
observ
sinc
administr
equal
effect
improv
resist
infant
mice
rsv
infect
reduc
lung
injuri
interestingli
although
show
similar
capac
reduc
lung
rsv
titer
effect
reduc
lung
injuri
rsv
infect
differenti
effect
achiev
four
treatment
would
relat
specif
capac
modul
product
rsv
challeng
abl
improv
respiratori
level
reduc
viral
load
increas
reduc
lung
injuri
result
suggest
heatkil
bacteria
deriv
immunobiot
strain
maintain
immunoregulatori
effect
heat
treatment
would
import
point
consid
select
immunoact
nonviabl
strain
previous
demonstr
nasal
treatment
malnourish
mice
heatkil
l
casei
abl
increas
resist
infect
respiratori
pathogen
pneumonia
result
studi
suggest
heatkil
lactobacilli
also
effect
immunomodul
respiratori
immun
system
immunocompromis
host
therefor
immunobiot
bacteria
form
live
cell
may
requir
enhanc
respiratori
defens
bacteri
viral
pathogen
previou
present
result
show
nonviabl
immunobiot
cellular
fraction
could
interest
altern
mucos
adjuv
especi
immunocompromis
host
use
live
bacteria
might
danger
addit
heatkil
immunobiot
advantag
allow
longer
product
shelflif
easier
storag
transport
therefor
studi
capac
nonviabl
cellular
fraction
benefici
modul
immun
respons
respiratori
viru
infect
immunocompet
immunocompromis
host
interest
topic
futur
research
present
work
demonstr
nasal
administr
immunobiot
abl
benefici
modul
immun
respons
trigger
activ
respiratori
tract
increas
resist
mice
challeng
rsv
report
oral
administ
probiot
bacteria
result
demonstr
immunoregulatori
effect
nasal
administ
lactobacilli
strain
depend
effect
compar
studi
use
two
lactobacillu
rhamnosu
strain
origin
similar
technolog
properti
show
strain
specif
immunoregulatori
effect
respiratori
tract
differenti
modul
immun
respons
poli
c
rsv
challeng
confer
differ
degre
protect
use
distinct
immun
mechan
also
demonstr
work
possibl
benefici
modul
respiratori
defens
rsv
use
heatkil
immunobiot
moreov
result
show
heatkil
bacteria
deriv
viabl
strain
immunomodulatori
capac
also
abl
function
modul
respiratori
immun
system
therefor
detail
studi
immunoregulatori
capac
heatkil
immunobiot
cellular
fraction
necessari
order
find
highest
potenti
use
improv
defens
respiratori
virus
bal
bronchoalveolar
lavag
bca
bicinchonin
acid
dc
dendrit
cell
dsrna
doublestrand
rna
elisa
enzymelink
immunosorb
assay
heatkil
lactobacillu
rhamnosu
heatkil
lactobacillu
rhamnosu
il
interleukin
ifn
interferon
lab
lactic
acid
bacteria
ldh
lactat
dehydrogenas
lactobacillu
rhamnosu
lactobacillu
rhamnosu
nad
nicotinamid
adenin
dinucleotid
pb
phosphat
buffer
salin
rigi
retino
acidinduc
gene
rsv
respiratori
syncyti
viru
tolllik
receptor
tnf
tumor
necrosi
factor
author
declar
compet
interest
yt
ec
hz
tt
kt
jv
carri
experi
analyz
data
perform
statist
analysi
hk
sa
jv
conceiv
studi
particip
design
coordin
help
draft
manuscript
author
read
approv
final
manuscript
studi
support
grantinaid
scientif
research
b
challeng
exploratori
research
japan
societi
promot
scienc
jsp
dr
h
kitazawa
grant
pip
ciunt
pict
dr
susana
alvarez
dr
julio
villena
j
villena
support
jsp
postdoctor
fellowship
foreign
research
program
funder
role
studi
design
data
collect
analysi
decis
publish
prepar
manuscript
